Is NBIO or PM a better dividend investment in 2026?

NBIO currently yields 666666.67% with a 5% 5-year dividend growth rate. PM yields 3.48% with 2.8% growth. The better choice depends on your goal: NBIO offers higher current income.

What is the dividend yield difference between NBIO and PM?

NBIO has a forward dividend yield of 666666.67% ($2.00/share annually). PM yields 3.48% ($5.76/share annually). The yield gap is 666663.19 percentage points.

Home › Compare › NBIO vs PM

NBIO vs PM: Dividend Comparison 2026

NBIO yields 666666.67% · PM yields 3.48%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NBIO wins by $8.275235618773884e+34M in total portfolio value

INVESTMENT

TIME HORIZON10 years

NBIO

● Live price

666666.67%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$8.275235618773884e+34M

Annual income

$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00

Full NBIO calculator →

Philip Morris International

● Live price

3.48%

Share price

$165.34

Annual div

$5.76

5Y div CAGR

17.2%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$49.6K

Annual income

$2,492.02

Full PM calculator →

Portfolio growth — NBIO vs PM

📍 NBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	NBIO	PM
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, NBIO + PM cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

NBIO pays

PM pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NBIO

Annual income on $10K today (after 15% tax)

$56,666,666.67/yr

After 10yr DRIP, annual income (after tax)

$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr

Annual income on $10K today (after 15% tax)

$296.12/yr

After 10yr DRIP, annual income (after tax)

$2,118.22/yr

At 15% tax rate, NBIO beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NBIO + PM for your $10,000?

NBIO: 50%PM: 50%

100% PM50/50100% NBIO

Portfolio after 10yr

$4.137617809386942e+34M

Annual income

$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.97%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

NBIO

No analyst data

Altman Z

-223.9

Piotroski

1/9

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$194.30

+17.5% upside vs current

Range: $180.00 — $205.00

Altman Z

4.0

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NBIO buys

PM buys

No recent congressional trades found for NBIO or PM in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricNBIOPM

Forward yield	666666.67% ✓	3.48%
Annual dividend / share	$2.00	$5.76 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	17.2% ✓
Portfolio after 10y	$8.275235618773884e+34M	$49.6K ✓
Annual income after 10y	$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00 ✓	$2,492.02
Total dividends collected	$8.275075881065991e+34M	$11.7K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples

Year-by-year: NBIO vs PM ($10,000, DRIP)

Year	NBIO Portfolio	NBIO Income/yr	PM Portfolio	PM Income/yr	Gap
1← crossover	$66,677,367	$66,666,666.67	$11,648	$408.29	+$66.67M → NBIO
2	$415,506,651,117	$415,435,306,334.37	$13,589	$495.90	+$415506.64M → NBIO
3	$2,419,908,598,386,268	$2,419,464,006,269,573.00	$15,877	$603.21	+$2419908598.37M → NBIO
4	$13,171,697,643,084,456,000	$13,169,108,340,884,183,000.00	$18,580	$734.88	+$13171697643084.44M → NBIO
5	$67,004,927,492,790,120,000,000	$66,990,833,776,312,020,000,000.00	$21,781	$896.75	+$67004927492790120.00M → NBIO
6	$318,562,277,003,514,840,000,000,000	$318,490,581,731,097,560,000,000,000.00	$25,578	$1,096.12	+$318562277003514871808.00M → NBIO
7	$1,415,484,168,853,553,000,000,000,000,000	$1,415,143,307,217,159,200,000,000,000,000.00	$30,092	$1,342.17	+$1.415484168853553e+24M → NBIO
8	$5,878,130,573,362,507,000,000,000,000,000,000	$5,876,616,005,301,833,000,000,000,000,000,000.00	$35,470	$1,646.46	+$5.878130573362507e+27M → NBIO
9	$22,813,793,009,840,743,000,000,000,000,000,000,000	$22,807,503,410,127,248,000,000,000,000,000,000,000.00	$41,892	$2,023.58	+$2.2813793009840744e+31M → NBIO
10	$82,752,356,187,738,840,000,000,000,000,000,000,000,000	$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00	$49,578	$2,492.02	+$8.275235618773884e+34M → NBIO

NBIO vs PM: Complete Analysis 2026

NBIO — Stock

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.

Full NBIO Calculator →

PM — Consumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →

📬

Get this NBIO vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NBIO vs SCHD NBIO vs JEPI NBIO vs O NBIO vs KO NBIO vs MAIN NBIO vs MO NBIO vs BTI NBIO vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.